The Roche Q3 2026 results are as much about the future as the quarter. Group sales of CHF 16.13 billion, up 7% at constant exchange rates, beat expectations on 22 October 2026, but the more telling details for the industry are the Xolair shortfall after a lower-priced competitor arrived, and the patent expiries now approaching for Ocrevus, Tecentriq and Hemlibra, which put pressure on Roche to find new growth through licensing.
Key takeaways: the Roche Q3 2026 results and the patent cliff
- Group sales rose 7% at constant exchange rates to CHF 16.13 billion, ahead of the company-compiled consensus of CHF 15.75 billion.
- Ocrevus sales grew 9% at constant currencies to CHF 1.84 billion.
- Xolair sales of CHF 848 million fell short of an expected CHF 925 million after the first cheaper copy launched.
- Ocrevus and Tecentriq are expected to face generic competition by 2030, with Hemlibra following, according to a trade-press report.
- Roche is relying on external deals, including a reported licence from China’s Hansoh Pharma.
What the Roche Q3 2026 results say about patent expiries
Several of Roche’s older blockbuster medicines are approaching patent expiry. A trade-press report says Ocrevus and Tecentriq face generic competition by 2030, with Hemlibra following in the early part of the next decade, and that these products accounted for four of Roche’s five best sellers in the third quarter. We have not seen Roche’s own expiry timetable, which is on its investor site.
The Xolair result is an early sign of the mechanism. The first lower-priced copy launched in the US this month, and Xolair sales came in at CHF 848 million against expectations of about CHF 925 million. By our own arithmetic that is a gap of roughly CHF 77 million, or 8%. The reports link the two, but they do not give data to show how much of the gap the competitor caused, and we do not claim a precise effect.
Biosimilars and the Roche Q3 2026 results
Lower-priced versions of biologic drugs are called biosimilars, and regulators such as the US Food and Drug Administration explain their approval on the FDA biosimilars page. Acumen Research and Consulting’s report Biosimilars Market Size, Share, Analysis, Trends and Forecast 2024 to 2032 puts the global market at USD 26.7 billion in 2023 and projects USD 113.2 billion by 2032, a CAGR of 17.5% over 2024 to 2032. It says North America led the market at around USD 10.7 billion in 2023, that Asia-Pacific is the fastest-growing region at more than 18.4% a year, and that monoclonal antibodies are expected to dominate.
Xolair is a monoclonal antibody, so the report’s segment is relevant. The Acumen figures describe the whole biosimilars market and are not a forecast for Xolair or for Roche.
How Roche is responding in the Roche Q3 2026 results
- Licensing: a reported agreement with Hansoh Pharma is worth more than USD 15 billion in total, with CHF 400 million upfront, according to reports; trade-press data cited in a report count 11 Chinese licensing deals since the start of 2025.
- Pipeline: the breast cancer pill giredestrant has an FDA decision expected by 18 December, and fenebrutinib for multiple sclerosis is awaiting an FDA answer.
- Obesity: Roche has said obesity drugs and giredestrant could together generate about USD 9 billion in peak annual sales.
Chief executive Thomas Schinecker said that about half of Roche’s external licensing deals over the past four years were made in the US and half in China and Asia, which he said shows where Europe stands on innovation. Those are his words as reported.
Regional picture in the Roche Q3 2026 results
North America accounts for nearly half of Roche’s group revenue, according to a wire-service report, which also says a stronger dollar against the Swiss franc eased the currency drag there. China recorded double-digit declines, although the drag from its healthcare pricing reforms is easing. Diagnostics grew 5% to CHF 3.54 billion, and the same report says it expects a return to mid- to high-single-digit growth next year, a company expectation that we have not verified. Shares fell 1.1% in morning trade on the day, which is a market reaction and not a judgement on the results.
General background: how a patent cliff works
When a patent or exclusivity ends, lower-priced competitors can enter. Insurers and pharmacy benefit managers can then change coverage, and patients can be switched quickly. Brand owners often respond with price cuts, new indications or new products. The timing and size of the effect differ by drug. See also our pharmaceutical coverage.
Our analysis: the Roche Q3 2026 results as a test of resilience
In our assessment, the Roche Q3 2026 results show a business still growing but aware of its calendar. Ocrevus growth shows that demand for key medicines remains strong. The Xolair miss shows how quickly a lower-priced rival can matter. And the licensing push shows how Roche plans to replace revenue.
We do not predict how the next patent expiries will play out. Each product has a different market, regulatory path and set of competitors. Nothing here is investment advice.
What is not disclosed in the Roche Q3 2026 results coverage
- The competing Xolair product and its price in the sources we reviewed.
- Roche’s own schedule of patent expiries.
- How much of the revenue beat came from the new planning system an analyst cited.
- Full terms of the Hansoh agreement beyond the reported headline figures.
Risks and caveats
This article relies on reports of the company announcement and on analyst comments, which are opinions. Consensus figures differ slightly between reports. Acumen’s market figures are third-party estimates. This is news reporting and not investment advice.
What to watch next
- Xolair sales in the fourth quarter.
- The giredestrant decision by 18 December.
- New licensing agreements.
- Roche’s full-year results and 2027 outlook.
FAQ
What do the Roche Q3 2026 results show?
Sales up 7% at constant exchange rates to CHF 16.13 billion, strong Ocrevus growth, and a Xolair shortfall.
When do Roche’s older drugs lose patent protection?
A trade-press report says Ocrevus and Tecentriq face generic competition by 2030, with Hemlibra later.
What does Acumen say about biosimilars?
It projects the global biosimilars market to grow from USD 26.7 billion in 2023 to USD 113.2 billion by 2032, a CAGR of 17.5%.
How we reported this: we relied on the company announcement, wire and trade-press reports, and the Acumen Research and Consulting report cited above, and attributed every figure. Last updated 23 October 2026. This is news reporting and not advice.
